Sep
14
2020
Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophrenia
Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its …